73 Pre-Radiotherapy Cognitive Profiles in Patients with Brain Metastases REFERENCES 1. Gerstenecker A, Nabors LB, Meneses K, et al. Cognition in patients with newly diagnosed brain metastasis: Profiles and implications. J Neurooncol 2014; 120: 179–185. 2. Achrol AS, Rennert RC, Anders C, et al. Brain metastases. Nat Rev Dis Primers; 5. Epub ahead of print 2019. DOI: 10.1038/s41572-018-0055-y. 3. Lambda N, Wen PY, Aizer AA. Epidemiology of Brain Metastases and Leptomingeal Disease. Neuro Oncol. 4. Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. American Journal of Clinical Oncology: Cancer Clinical Trials 1982; 5: 649–656. 5. Gaspar L, Scott C, Rotman M, et al. Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials. Int J Radiat Oncol Biol Phys 1997; 37: 745–751. 6. Sperduto PW, Kased N, Roberge D, et al. Summary report on the graded prognostic assessment: An accurate and facile diagnosis-specific tool to estimate survival for patients with brain metastases. Journal of Clinical Oncology 2012; 30: 419–425. 7. Sperduto PW, Chao ST, Sneed PK, et al. Diagnosis-specific prognostic factors, indexes, and treatment outcomes for patients with newly diagnosed brain metastases: a multi-institutional analysis of 4,259 patients. Int J Radiat Oncol Biol Phys 2010; 77: 655–661. 8. Eichler AF, Loeffler JS. Multidisciplinary management of brain metastases. Oncologist 2007; 12: 884–898. 9. Van Grinsven EE, Nagtegaal SHJ, Verhoeff JJC, et al. The Impact of Stereotactic or Whole Brain Radiotherapy on Neurocognitive Functioning in Adult Patients with Brain Metastases: A Systematic Review and Meta-Analysis. Oncol Res Treat 2021; 44: 622–636. 10. Mehta MP, Rodrigus P, Terhaard CHJ, et al. Survival and neurologic outcomes in a randomized trial of motexafin gadolinium and whole-brain radiation therapy in brain metastases. Journal of Clinical Oncology 2003; 21: 2529–2536. 11. Chang EL, Wefel JS, Maor MH, et al. A pilot study of neurocognitive function in patients with one to three new brain metastases initially treated with stereotactic radiosurgery alone. Neurosurgery 2007; 60: 277–283. 12. Habets EJJ, Dirven L, Wiggenraad RG, et al. Neurocognitive functioning and health-related quality of life in patients treated with stereotactic radiotherapy for brain metastases: A prospective study. Neuro Oncol 2016; 18: 435–444. 13. Schimmel WCM, Gehring K, Hanssens PEJ, et al. Cognitive functioning and predictors thereof in patients with 1–10 brain metastases selected for stereotactic radiosurgery. J Neurooncol 2019; 145: 265–276. 14. Steinmann D, Schäfer C, van Oorschot B, et al. Effects of Radiotherapy for Brain Metastases on Quality of Life (QoL). Strahlentherapie und Onkologie 2009; 185: 190–197. 15. Meyers CA, Smith JA, Bezjak A, et al. Neurocognitive function and progression in patients with brain metastases treated with whole-brain radiation and motexafin gadolinium: results of a randomized phase III trial. Journal of Clinical Oncology 2004; 22: 157–165. 3
RkJQdWJsaXNoZXIy MTk4NDMw